Case reports in oncology · 2026
Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma Occurring in Spleen of a Patient after Chemotherapy for Lung Carcinoma: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morishige Takushi, Hirazawa Katsutoshi, Tanaka Akira, Osoreda Hisayuki, Sato Takashi, Ikeda Eiji
Аннотация
INTRODUCTION: Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV+ inflammatory FDCS) is a rare neoplasm that occurs almost exclusively in the spleen and liver. Although EBV+ inflammatory FDCS is recognized to show indolent behavior, its pathophysiology including the pathogenesis remains unclear.
CASE PRESENTATION: We present an EBV+ inflammatory FDCS, which occurred in the spleen of a patient under the follow-up for chemotherapy against lung carcinoma. Sequential CT examinations reveal that a splenic lesion was first detectable 5 years after chemotherapy and has grown for another 3 years to form a mass of 4 cm in diameter. Splenectomy was performed. Histologically, a well-circumscribed lesion in the spleen exhibited the significant infiltration of lymphocytes and plasma cells in the background of hyalinized fibrous tissue, and large oval-shaped cells were intermingled with lymphocytes and plasma cells. Large oval-shaped cells were found to express CD21 and CD23, and they were shown to be positive for EBV-encoded small RNA in situ hybridization. Based on these findings, the splenic lesion was diagnosed as EBV+ inflammatory FDCS.
CONCLUSION: The present case might provide information to discuss the possible pathogenesis of EBV+ inflammatory FDCS in the context of immunosuppression.
CASE PRESENTATION: We present an EBV+ inflammatory FDCS, which occurred in the spleen of a patient under the follow-up for chemotherapy against lung carcinoma. Sequential CT examinations reveal that a splenic lesion was first detectable 5 years after chemotherapy and has grown for another 3 years to form a mass of 4 cm in diameter. Splenectomy was performed. Histologically, a well-circumscribed lesion in the spleen exhibited the significant infiltration of lymphocytes and plasma cells in the background of hyalinized fibrous tissue, and large oval-shaped cells were intermingled with lymphocytes and plasma cells. Large oval-shaped cells were found to express CD21 and CD23, and they were shown to be positive for EBV-encoded small RNA in situ hybridization. Based on these findings, the splenic lesion was diagnosed as EBV+ inflammatory FDCS.
CONCLUSION: The present case might provide information to discuss the possible pathogenesis of EBV+ inflammatory FDCS in the context of immunosuppression.